Search

Your search keyword '"Nam, Jackie"' showing total 153 results
Start Over Author "Nam, Jackie"
153 results on '"Nam, Jackie"'

1. The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials

Author

Takase-Minegishi, Kaoru, primary, Böhringer, Stefan, additional, Nam, Jackie L, additional, Kaneko, Yuko, additional, Behrens, Frank, additional, Saevarsdottir, Saedis, additional, Detert, Jacqueline, additional, Leirisalo-Repo, Marjatta, additional, van der Heijde, Désirée, additional, Landewé, Robert, additional, Ramiro, Sofia, additional, and van der Woude, Diane, additional

Published
2024
Full Text
View/download PDF

3. Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients

Author

Taylor, John C., Bongartz, Tim, Massey, Jonathan, Mifsud, Borbala, Spiliopoulou, Athina, Scott, Ian C., Wang, Jianmei, Morgan, Michael, Plant, Darren, Colombo, Marco, Orchard, Peter, Twigg, Sarah, McInnes, Iain B., Porter, Duncan, Freeston, Jane E., Nam, Jackie L., Cordell, Heather J., Isaacs, John D., Strathdee, Jenna L., Arnett, Donna, de Hair, Maria J. H., Tak, Paul P., Aslibekyan, Stella, van Vollenhoven, Ronald F., Padyukov, Leonid, Bridges, S. Louis, Pitzalis, Costantino, Cope, Andrew P., Verstappen, Suzanne M. M., Emery, Paul, Barnes, Michael R., Agakov, Felix, McKeigue, Paul, Mushiroda, Taisei, Kubo, Michiaki, Weinshilboum, Richard, Barton, Anne, Morgan, Ann W., Barrett, Jennifer H., on behalf of the MATURA, and PAMERA, and Consortia

Published
2018
Full Text
View/download PDF

4. Actin-mediated endocytosis in the E-YSL helps drive epiboly in zebrafish

Author

Cheng, Chong Nam Jackie, Miller, Andrew Leitch, Webb, Sarah E, Cheng, Chong Nam Jackie, Miller, Andrew Leitch, and Webb, Sarah E

Abstract

In zebrafish, a punctate band of F-actin is reported to develop in the external yolk syncytial layer (E-YSL) during the latter part of epiboly in zebrafish embryos. Here, electron microscopy (EM) and fluorescence confocal microscopy were conducted to investigate dynamic changes in the E-YSL membrane during epiboly. Using scanning EM, we report that the surface of the E-YSL is highly convoluted, consisting of a complex interwoven network of branching membrane surface microvilli-like protrusions. The region of membrane surface protrusions was relatively wide at 30% epiboly but narrowed as epiboly progressed. This narrowing was coincident with the formation of the punctate actin band. We also demonstrated using immunogold transmission EM that actin clusters were localized at the membrane surface mainly within the protrusions as well as in deeper locations of the E-YSL. Furthermore, during the latter part of epiboly, the punctate actin band was coincident with a region of highly dynamic endocytosis. Treatment with cytochalasin B led to the disruption of the punctate actin band and the membrane surface protrusions, as well as the attenuation of endocytosis. Together, our data suggest that, in the E-YSL, the region encompassing the membrane surface protrusions and its associated punctate actin band are likely to be an integral part of the localized endocytosis, which is important for the progression of epiboly in zebrafish embryos.

Published
2023

8. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Author

Smolen, Josef S, Landewé, Robert, Breedveld, Ferdinand C, Buch, Maya, Burmester, Gerd, Dougados, Maxime, Emery, Paul, Gaujoux-Viala, Cécile, Gossec, Laure, Nam, Jackie, Ramiro, Sofia, Winthrop, Kevin, de Wit, Maarten, Aletaha, Daniel, Betteridge, Neil, Bijlsma, Johannes W J, Boers, Maarten, Buttgereit, Frank, Combe, Bernard, Cutolo, Maurizio, Damjanov, Nemanja, Hazes, Johanna M W, Kouloumas, Marios, Kvien, Tore K, Mariette, Xavier, Pavelka, Karel, van Riel, Piet L C M, Rubbert-Roth, Andrea, Scholte-Voshaar, Marieke, Scott, David L, Sokka-Isler, Tuulikki, Wong, John B, and van der Heijde, Désirée

Published
2014
Full Text
View/download PDF

18. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Author

Smolen, Josef S, Landewé, Robert, Breedveld, Ferdinand C, Dougados, Maxime, Emery, Paul, Gaujoux-Viala, Cecile, Gorter, Simone, Knevel, Rachel, Nam, Jackie, Schoels, Monika, Aletaha, Daniel, Buch, Maya, Gossec, Laure, Huizinga, Tom, Bijlsma, Johannes W, Burmester, Gerd, Combe, Bernard, Cutolo, Maurizio, Gabay, Cem, Gomez-Reino, Juan, Kouloumas, Marios, Kvien, Tore K, Martin-Mola, Emilio, McInnes, Iain, Pavelka, Karel, van Riel, Piet, Scholte, Marieke, Scott, David L, Sokka, Tuulikki, Valesini, Guido, van Vollenhoven, Ronald, Winthrop, Kevin L, Wong, John, Zink, Angela, and van der Heijde, Désirée

Published
2010
Full Text
View/download PDF

20. Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis

Author

Hensor, Elizabeth M A, McKeigue, Paul, Ling, Stephanie F, Colombo, Marco, Barrett, Jennifer H, Nam, Jackie L, Freeston, Jane, Buch, Maya H, Spiliopoulou, Athina, Agakov, Felix, Kelly, Stephen, Lewis, Myles J, Verstappen, Suzanne M M, MacGregor, Alexander J, Viatte, Sebastien, Barton, Anne, Pitzalis, Costantino, Emery, Paul, Conaghan, Philip G, and Morgan, Ann W

Subjects
rheumatoid arthritis, musculoskeletal diseases, DAS28, ultrasonography, Clinical Science, synovitis
Abstract

OBJECTIVES: Imaging of joint inflammation provides a standard against which to derive an updated DAS for RA. Our objectives were to develop and validate a DAS based on reweighting the DAS28 components to maximize association with US-assessed synovitis.METHODS: Early RA patients from two observational cohorts (n = 434 and n = 117) and a clinical trial (n = 59) were assessed at intervals up to 104 weeks from baseline; all US scans were within 1 week of clinical exam. There were 899, 163 and 183 visits in each cohort. Associations of combined US grey scale and power Doppler scores (GSPD) with 28 tender joint count and 28 swollen joint count (SJC28), CRP, ESR and general health visual analogue scale were examined in linear mixed model regressions. Cross-validation evaluated model predictive ability. Coefficients learned from training data defined a re-weighted DAS28 that was validated against radiographic progression in independent data (3037 observations; 717 patients).RESULTS: Of the conventional DAS28 components only SJC28 and CRP were associated with GSPD in all three development cohorts. A two-component model including SJC28 and CRP outperformed a four-component model (R2 = 0.235, 0.392, 0.380 vs 0.232, 0.380, 0.375, respectively). The re-weighted two-component DAS28CRP outperformed conventional DAS28 definitions in predicting GSPD (Δtest log-likelihood CONCLUSION: A score based on SJC28 and CRP alone demonstrated stronger associations with synovitis and radiographic progression than the original DAS28 and should be considered in research on pathophysiological manifestations of early RA. Implications for clinical management of RA remain to be established.

Published
2019

21. Validity of a 2-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis

Author

Hensor, Elizabeth M A, McKeigue, Paul, Ling, Stephanie, Colombo, Marco, Barrett, Jennifer H, Nam, Jackie L., Freeston, Jane, Buch, Maya, Spiliopoulou, Athina, Agakov, Felix, Kelly, Stephen, Verstappen, Suzanne, MacGregor, Alexander J, Viatte, Sebastien, Barton, Anne, Pitzalis, Costantino, Emery, Paul, Conaghan, Philip G, and Morgan, Ann W

Subjects
musculoskeletal diseases, ResearchInstitutes_Networks_Beacons/MICRA, Lydia Becker Institute, Manchester Institute for Collaborative Research on Ageing, ResearchInstitutes_Networks_Beacons/lydia_becker_institute_of_immunology_and_inflammation, DAS28, ultrasonography, Rheumatoid arthritis, synovitis
Abstract

Objectives: Imaging of joint inflammation provides a standard against which to derive an updated disease activity score (DAS) for rheumatoid arthritis (RA). Our objectives were to develop and validate a DAS based on reweighting the DAS28 components to maximize association with ultrasound-assessed synovitis.Methods: Early RA patients from two observational cohorts (n=434 & n=117), and a clinical trial (n=59) were assessed at intervals up to 104 weeks from baseline; all ultrasound scans were within 1 week of clinical exam. There were 899, 163 and 183 visits in each cohort. Associations of combined ultrasound grey scale and power Doppler scores (GSPD) with TJC28 & SJC28, CRP, ESR, general health visual analogue scale were examined in linear mixed model regressions. Cross-validation evaluated model predictive ability; coefficients learned from training data defined a re-weighted DAS28 which was validated against radiographic progression in independent data (3037 observations; 717 patients).Results: Of the conventional DAS28 components only SJC28 and CRP were associated with GSPD in all three development cohorts. A 2-component model including SJC28 and CRP outperformed a 4-component model (R-squared 0.235, 0.392, 0.380 vs. 0.232, 0.380, 0.375 respectively). The re-weighted 2-component DAS28CRP outperformed conventional DAS28 definitions in predicting GSPD (Δtest log-likelihoodConclusion: A score based on SJC28 and CRP alone demonstrated stronger associations with synovitis and radiographic progression than the original DAS28 and should be considered in research on pathophysiological manifestations of early RA. Implications for clinical management of RA remain to be established.

Published
2019

22. Prevalence of Periodontal Disease and Periodontopathic Bacteria in Anti–Cyclic Citrullinated Protein Antibody–Positive At-Risk Adults Without Arthritis

Author

Mankia, Kulveer, primary, Cheng, Zijian, additional, Do, Thuy, additional, Hunt, Laura, additional, Meade, Josephine, additional, Kang, Jing, additional, Clerehugh, Val, additional, Speirs, Alastair, additional, Tugnait, Aradhna, additional, Hensor, Elizabeth M. A., additional, Nam, Jackie L., additional, Devine, Deirdre A., additional, and Emery, Paul, additional

Published
2019
Full Text
View/download PDF

23. Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis

Author

Mortimer, Isabel, primary, Bissell, Lesley-Anne, additional, Hensor, Elizabeth M. A., additional, Kozera, Lukasz, additional, Mackie, Sarah L., additional, Burska, Agata N., additional, Nam, Jackie L., additional, Keen, Helen, additional, Villeneuve, Edith, additional, Donica, Helena, additional, Buch, Maya H., additional, Conaghan, Philip G., additional, Emery, Paul, additional, Morgan, Ann W., additional, and Andrews, Jacqueline, additional

Published
2019
Full Text
View/download PDF

24. Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis

Author

Hensor, Elizabeth M A, primary, McKeigue, Paul, additional, Ling, Stephanie F, additional, Colombo, Marco, additional, Barrett, Jennifer H, additional, Nam, Jackie L, additional, Freeston, Jane, additional, Buch, Maya H, additional, Spiliopoulou, Athina, additional, Agakov, Felix, additional, Kelly, Stephen, additional, Lewis, Myles J, additional, Verstappen, Suzanne M M, additional, MacGregor, Alexander J, additional, Viatte, Sebastien, additional, Barton, Anne, additional, Pitzalis, Costantino, additional, Emery, Paul, additional, Conaghan, Philip G, additional, and Morgan, Ann W, additional

Published
2019
Full Text
View/download PDF

25. The new ACR/EULAR criteria for rheumatoid arthritis can identify patients with same disease activity but less damage by ultrasound

Author

Aydın, Sibel Zehra, Castillo-Gallego, Concepcion, Nam, Jackie, Freeston, Jane, Horton, Sarah, Wakefield, Richard J, and Emery, Paul

Subjects
musculoskeletal diseases, immune system diseases, ultrasound, Rheumatoid arthritis, skin and connective tissue diseases, doppler
Abstract

We aimed to compare the ultrasound findings of patients fulfilling the 1987 ACR [OLD-rheumatoid arthritis (RA)] and the new ACR/EULAR (NEW-RA) classification criteria to examine the impact of the new criteria on disease characteristics, particularly disease duration.

Published
2017

30. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

Author

Smolen, Josef S., Landewe, Robert, Bijlsma, Johannes, Burmester, Gerd, Chatzidionysiou, Katerina, Dougados, Maxime, Nam, Jackie, Ramiro, Sofia, Voshaar, Marieke, van Vollenhoven, Ronald, Aletaha, Daniel, Aringer, Martin, Boers, Maarten, Buckley, Chris D., Buttgereit, Frank, Bykerk, Vivian, Cardiel, Mario, Combe, Bernard, Cutolo, Maurizio, van Eijk-Hustings, Yvonne, Emery, Paul, Finckh, Axel, Gabay, Cem, Gomez-Reino, Juan, Gossec, Laure, Gottenberg, Jacques-Eric, Hazes, Johanna M. W., Huizinga, Tom, Jani, Meghna, Karateev, Dmitry, Kouloumas, Marios, Kvien, Tore, Li, Zhanguo, Mariette, Xavier, McInnes, Iain, Mysler, Eduardo, Nash, Peter, Pavelka, Karel, Poor, Gyula, Richez, Christophe, van Riel, Piet, Rubbert-Roth, Andrea, Saag, Kenneth, da Silva, Jose, Stamm, Tanja, Takeuchi, Tsutomu, Westhovens, Rene, de Wit, Maarten, van der Heijde, Desiree, Smolen, Josef S., Landewe, Robert, Bijlsma, Johannes, Burmester, Gerd, Chatzidionysiou, Katerina, Dougados, Maxime, Nam, Jackie, Ramiro, Sofia, Voshaar, Marieke, van Vollenhoven, Ronald, Aletaha, Daniel, Aringer, Martin, Boers, Maarten, Buckley, Chris D., Buttgereit, Frank, Bykerk, Vivian, Cardiel, Mario, Combe, Bernard, Cutolo, Maurizio, van Eijk-Hustings, Yvonne, Emery, Paul, Finckh, Axel, Gabay, Cem, Gomez-Reino, Juan, Gossec, Laure, Gottenberg, Jacques-Eric, Hazes, Johanna M. W., Huizinga, Tom, Jani, Meghna, Karateev, Dmitry, Kouloumas, Marios, Kvien, Tore, Li, Zhanguo, Mariette, Xavier, McInnes, Iain, Mysler, Eduardo, Nash, Peter, Pavelka, Karel, Poor, Gyula, Richez, Christophe, van Riel, Piet, Rubbert-Roth, Andrea, Saag, Kenneth, da Silva, Jose, Stamm, Tanja, Takeuchi, Tsutomu, Westhovens, Rene, de Wit, Maarten, and van der Heijde, Desiree

Abstract

Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (Janus kinase (Jak) inhibitors tofacitinib, baricitinib). Monotherapy, combination therapy, treatment strategies (treat-to-target) and the targets of sustained clinical remission (as defined by the American College of Rheumatology-(ACR)-EULAR Boolean or index criteria) or low disease activity are discussed. Cost aspects were taken into consideration. As first strategy, the Task Force recommends MTX (rapid escalation to 25 mg/week) plus short-term GC, aiming at >50% improvement within 3 and target attainment within 6 months. If this fails stratification is recommended. Without unfavourable prognostic markers, switching to-or adding-another csDMARDs (plus short-term GC) is suggested. In the presence of unfavourable prognostic markers (autoantibodies, high disease activity, early erosions, failure of 2 csDMARDs), any bDMARD (current practice) or Jak-inhibitor should be added to the csDMARD. If this fails, any other bDMARD or tsDMARD is recommended. If a patient is in sustained remission, bDMARDs can be tapered. For each recommendation, levels of evidence and Task Force agreement are provided, both mostly very high. These recommendations intend informing rheumatologists, patients, national rheumatolog

Published
2017

34. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis

Author

Chatzidionysiou, Katerina, primary, Emamikia, Sharzad, additional, Nam, Jackie, additional, Ramiro, Sofia, additional, Smolen, Josef, additional, van der Heijde, Désirée, additional, Dougados, Maxime, additional, Bijlsma, Johannes, additional, Burmester, Gerd, additional, Scholte, Marieke, additional, van Vollenhoven, Ronald, additional, and Landewé, Robert, additional

Published
2017
Full Text
View/download PDF

35. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis

Author

Ramiro, Sofia, primary, Sepriano, Alexandre, additional, Chatzidionysiou, Katerina, additional, Nam, Jackie L, additional, Smolen, Josef S, additional, van der Heijde, Désirée, additional, Dougados, Maxime, additional, van Vollenhoven, Ronald, additional, Bijlsma, Johannes W, additional, Burmester, Gerd R, additional, Scholte-Voshaar, Marieke, additional, Falzon, Louise, additional, and Landewé, Robert B M, additional

Published
2017
Full Text
View/download PDF

36. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis

Author

Nam, Jackie L, primary, Takase-Minegishi, Kaoru, additional, Ramiro, Sofia, additional, Chatzidionysiou, Katerina, additional, Smolen, Josef S, additional, van der Heijde, Désirée, additional, Bijlsma, Johannes W, additional, Burmester, Gerd R, additional, Dougados, Maxime, additional, Scholte-Voshaar, Marieke, additional, van Vollenhoven, Ronald, additional, and Landewé, Robert, additional

Published
2017
Full Text
View/download PDF

37. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

Author

Smolen, Josef S, primary, Landewé, Robert, additional, Bijlsma, Johannes, additional, Burmester, Gerd, additional, Chatzidionysiou, Katerina, additional, Dougados, Maxime, additional, Nam, Jackie, additional, Ramiro, Sofia, additional, Voshaar, Marieke, additional, van Vollenhoven, Ronald, additional, Aletaha, Daniel, additional, Aringer, Martin, additional, Boers, Maarten, additional, Buckley, Chris D, additional, Buttgereit, Frank, additional, Bykerk, Vivian, additional, Cardiel, Mario, additional, Combe, Bernard, additional, Cutolo, Maurizio, additional, van Eijk-Hustings, Yvonne, additional, Emery, Paul, additional, Finckh, Axel, additional, Gabay, Cem, additional, Gomez-Reino, Juan, additional, Gossec, Laure, additional, Gottenberg, Jacques-Eric, additional, Hazes, Johanna M W, additional, Huizinga, Tom, additional, Jani, Meghna, additional, Karateev, Dmitry, additional, Kouloumas, Marios, additional, Kvien, Tore, additional, Li, Zhanguo, additional, Mariette, Xavier, additional, McInnes, Iain, additional, Mysler, Eduardo, additional, Nash, Peter, additional, Pavelka, Karel, additional, Poór, Gyula, additional, Richez, Christophe, additional, van Riel, Piet, additional, Rubbert-Roth, Andrea, additional, Saag, Kenneth, additional, da Silva, Jose, additional, Stamm, Tanja, additional, Takeuchi, Tsutomu, additional, Westhovens, René, additional, de Wit, Maarten, additional, and van der Heijde, Désirée, additional

Published
2017
Full Text
View/download PDF

41. Effect of Fatigue, Older Age, Higher Body Mass Index, and Female Sex on Disability in Early Rheumatoid Arthritis in the Treatment‐to‐Target Era

Author

Twigg, Sarah, Hensor, Elizabeth M. A., Freeston, Jane, Tan, Ai Lyn, Emery, Paul, Tennant, Alan, Morgan, Ann W., Conaghan, Philip, Keenan, Anne‐Maree, Hensor, Elizabeth, Quinn, Mark, Gough, Andrew, Green, Michael, Reece, Richard, Hordon, Lesley, Helliwell, Philip, Melsom, Richard, Doherty, Sheelagh, Adebajo, Ade, Harvey, Andrew, Jarrett, Steve, Huston, Gareth, Isdale, Amanda, Martin, Mike, Karim, Zunaid, McGonagle, Dennis, Pease, Colin, Cox, Sally, Bejarano, Victoria, Nam, Jackie, Villeneuve, Edith, Brown, Claire, Thomas, Christine, Pickles, David, Hammond, Alison, Neville, Beverley, Fairclough, Alan, Nunns, Caroline, Gill, Anne, Green, Julie, Rhys‐Evans, Belinda, Padwell, Barbara, Madden, Julie, Taylor, Lynda, Smith, Sally, King, Heather, Firth, Jill, Heard, Jayne, Sigsworth, Linda, Corscadden, Diane, Henshaw, Karen, Rashid, Lubna‐Haroon, Martin, Stephen, Robinson, James, Kozera, Lukasz, Burksa, Agata, Fahy, Sarah, Paterson, Andrea, Hensor, Elizabeth, Ponchel, Frederique, Buch, Maya, Nam, Jackie, Villeneuve, Edith, Conaghan, Philip, Andrews, Jacqueline, Wakefield, Richard, McGonagle, Denis, Marzo‐Ortega, Helena, Das, Sudipto, Horton, Sarah, Mackie, Sarah, Thomas, Rebecca, Bissell, Lesley Ann, Rakieh, Chadi, Ash, Zoe, Aslam, Amir, Saleem, Benazir, Coates, Laura, Fazal, Fahad, Hunt, Laura, Vital, Ed, Ferguson, Esme, Else, Sara, Tran, Gui, Zayat, Ahmed, Abignano, Guiseppina, Yousef, Yuz, Raghunath, Radhika, Mathieson, Hannah, Ramakumain, Chitra, Gul, Hanna, Mahmood, Mahwish, Fitzgerald, Pauline, Robinson, Matthew, Ward, Jason, Wells, Beverly, Pickles, David, Wordsworth, Oliver, Thomas, Christine, McManus, Alison, Bailey, Lynda, Gray, Linda, Fitzgerald, Pauline, Russell, Kate, Davies, Jayne, Corscadden, Diane, Henshaw, Karen, Rashid, Lubna‐Haroon, Martin, Stephen, Robinson, James, Kozera, Lukasz, Burksa, Agata, Mbara, Katie, Fahy, Sarah, Halsted‐Rastrick, Jill, Connoly‐Thompson, Ged, Thompson, Jonathan, Weatherill, Ian, Paterson, Andrea, Horton, Laura, Jackson, Alwyn, and Hodgson, Richard

Abstract

To compare disease activity and disability over 2 years in early rheumatoid arthritis (RA) before and after implementation of treat‐to‐target therapy and identify predictors of adverse outcome. The Yorkshire Early Arthritis Register (YEAR) recruited 725 patients with early RAbetween 2002 and 2009, treated with a step‐up approach. The Inflammatory Arthritis Continuum study (IACON) recruited cases between 2010 and 2014 and treated to target. A total of 384 IACONcases met 2010 American College of Rheumatology/European League Against Rheumatism criteria. Latent growth curves of change in Disease Activity Score in 28 joints (DAS28) and the Health Assessment Questionnaire (HAQ) were compared between YEARand IACON. Latent class growth analysis identified trajectories of change. Baseline predictors of trajectories were identified using logistic regression. The mean DAS28 over 2 years was lower in IACONthan in YEAR. Latent trajectories of HAQchange in YEARwere high stable (21% of cohort), moderate reducing (35%), and low reducing (44%). Only moderate reducing (66%) and low reducing (34%) were seen in IACON. In both cohorts, female sex and fatigue predicted adverse HAQtrajectories (high stable and moderate reducing). Odds ratios (ORs) for moderate reducing compared to low reducing for women were 2.58 (95% confidence interval [95% CI] 1.69, 4.49) in YEARand 5.81 (95% CI2.44, 14.29) in IACON. ORs per centimeter fatigue visual analog score were 1.13 (95% CI1.07, 1.20) in YEARand 1.16 (95% CI1.12, 1.20) in IACON. Treat‐to‐target therapy gave more favorable trajectories of change in DAS28 and HAQ, but adverse HAQtrajectory was more likely in women with greater fatigue, suggesting such patients would benefit from interventions to improve function as well as reduce inflammation.

Published
2018
Full Text
View/download PDF

42. Identification of a distinct imaging phenotype may improve the management of palindromic rheumatism.

Author

Mankia, Kulveer, D'Agostino, Maria-Antonietta, Wakefield, Richard J., Nam, Jackie L., Mahmood, Waqar, Grainger, Andrew J., and Emery, Paul

Subjects
DOPPLER ultrasonography, COMPARATIVE studies, JOINTS (Anatomy), LONGITUDINAL method, MAGNETIC resonance imaging, RESEARCH methodology, MEDICAL cooperation, RESEARCH, RESEARCH evaluation, RESEARCH funding, RHEUMATOID arthritis, TENOSYNOVITIS, PHENOTYPES, SYNOVITIS, EVALUATION research, ARTHRITIS Impact Measurement Scales
Abstract

Objectives: To use high-resolution imaging to characterise palindromic rheumatism (PR) and to compare the imaging pattern observed to that seen in new-onset rheumatoid arthritis (NORA).Methods: Ultrasound (US) assessment of synovitis, tenosynovitis and non-synovial extracapsular inflammation (ECI) was performed during and between flares in a prospective treatment-naive PR cohort. MRI of the flaring region was performed where possible. For comparison, the same US assessment was also performed in anticyclic citrullinated peptide (CCP) positive individuals with musculoskeletal symptoms (CCP+ at risk) and patients with NORA.Results: Thirty-one of 79 patients with PR recruited were assessed during a flare. A high frequency of ECI was identified on US; 19/31 (61%) of patients had ECI including 12/19 (63%) in whom ECI was identified in the absence of synovitis. Only 7/31 (23%) patients with PR had synovitis (greyscale ≥1 and power Doppler ≥1) during flare. In the hands/wrists, ECI was more prevalent in PR compared with NORA and CCP+ at risk (65% vs 29 % vs 6%, p<0.05). Furthermore, ECI without synovitis was specific for PR (42% PR vs 4% NORA (p=0.003) and 6% CCP+ at risk (p=0.0012)). Eleven PR flares were captured by MRI, which was more sensitive than US for synovitis and ECI. 8/31 (26%) patients with PR developed RA and had a similar US phenotype to NORA at progression.Conclusion: PR has a distinct US pattern characterised by reversible ECI, often without synovitis. In patients presenting with new joint swelling, US may refine management by distinguishing relapsing from persistent arthritis. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

43. Contributors

Author

Abelson, Abby G., Abramson, Steven B., Adachi, Jonathan D., Adams, Michael A., Aggarwal, Rohit, Aigner, Thomas, Akira, Shizuo, Albert, Daniel A., Aletaha, Daniel, Alevizos, Ilias, Allem, Kavitta B., Almehthel, Mohammed, Almohaya, Mohamed, Alonso, Elena Riera, Amigo, Mary-Carmen, Arden, Nigel K., Aringer, Martin, Arkema, Elizabeth V., Ascherman, Dana P., Atamas, Sergei P., Atkinson, Timothy J., Azeez, Maha A., Azevedo, Pedro M., Baer, Alan N., Baeten, Dominique, Baines, Colin P., Balsa, Alejandro, Baraliakos, Xenofon, Bardin, Thomas, Barnes, Jammie K., Barnsley, Les, Barr, Andrew J., Bathon, Joan M., Bauch, Angela, Bay-Jensen, Anne-Christine, Belch, Jill J.F., Bellamy, Nicholas, Bellido, Teresita, Benjamin, Michael, Bennell, Kim L., Beresford, Michael W., Berman, Brian, Bermas, Bonnie L., Bertsias, George, Bhalla, Sonal, Bilginer, Yelda, Birnbaum, Julius, Bleasel, Jane F., Block, Joel A., Blom, Ashley W., Böhm, Markus, Bonelli, Michael, Borchert, Grace, Boros, Christina A., Boumpas, Dimitrios T., Bozec, Aline, Brasington, Richard D., Jr., Braun, Jürgen, Brouwer, Elisabeth, Brown, Jacques P., Brown, Matthew A., Bruce, Ian N., Buch, Maya H., Buckley, Christopher D., Bugbee, William D., Burmester, Gerd-Rüdiger, Burns, Jane C., Burr, David B., Buttgereit, Frank, Bykerk, Vivian P., Calabrese, Leonard H., Callen, Jeffrey P., Carr, Andrew J., Carroll, Graeme J., Cavallo, Sabrina, Cervera, Ricard, Chaudhary, Prateek, Choi, Hyon K., Choy, Ernest H., Christopher-Stine, Lisa, Chu, Alvina D., Chung, Lorinda, Ciccia, Francesco, Clauw, Daniel J., Clinch, Jacqui, Clowse, Megan E.B., Coghlan, J. Gerard, Colbert, Robert A., Conaghan, Philip G., Cooper, Cyrus, Cooper, Robert G., Costenbader, Karen H., Cox, George L.D., Creamer, Paul, Cronstein, Bruce N., Cross, Raymond, Cutolo, Maurizio, D’Adamo, Chris, D’Agati, Vivette D., Daikh, David I., Dakin, Stephanie G., Dalbeth, Nicola, Davis, Aileen M., D’Cruz, David P., Ceulaer, Karel De, Rheum, Dipl, de Jesus, Adriana A., De Vita, Salvatore, de Wit, Maarten, Deal, Chad L., Deane, Kevin D., Dellaripa, Paul F., Dennison, Elaine, Denton, Christopher P., Dieppe, Paul, Dolan, Patricia, Doyle, Tracy J., Dyer, George S.M., Emery, Paul, Espinosa, Gerard, Espinoza, Luis R., Eyre, Stephen, Fanouriakis, Antonis C., Farber, Joshua, Fasth, Anders, Feist, Eugen, Feldman, Candace H., Feldman, Debbie, Filer, Andrew, Fiorentino, David F., Fisher, Benjamin A., Fisk, John D., Flores, Raymond H., Forbess, Lindsy, Fox, David A., Freemont, Anthony J., Fricka, Kevin B., Gabay, Cem, Gadina, Massimo, Gandolfo, Saviana, Gauntlett-Gilbert, Jeremy, Gay, Steffen, Gensler, Lianne S., Gerlag, Danielle M., Gold, Garry E., Goldbach-Mansky, Raphaela, Goldingay, Sarah J., Gómez-Puerta, José A., Goodman, Susan M., Gordon, Caroline, Gordon, Sharon M., Gorodkin, Rachel, Görtz, Simon, Grainger, Andrew J., Gravallese, Ellen M., Greenberg, Jeffrey D., Grieve, Sharon, Guilherme, Luiza, Gül, Ahmet, Gupta, Sarthak, Hagan, Matilda, Hagley, Karlene, Han, Shuhong, Hanly, John G., Hanson, Eric P., Haraoui, Boulos, Hardcastle, Sarah A., Harley, John B., Haroun, Tayseer G., Hashkes, Philip J., Hassan, Andrew Bassim, Haupt, Lukas, Hawker, Gillian A., Hawkins, Philip N., Heeringa, Peter, Heiberg, Turid, Heinegård, Dick, Helfgott, Simon M., Henriksen, Kim, Hinman, Rana S., Ho, Pauline Y.P., Hochberg, Marc C., Hoffmann, Markus H., Holick, Michael F., Holroyd, Christopher R., Holt, Cathy, Huizinga, Thomas W.J., Husni, M. Elaine, Inman, Robert D., Inoue, Dai, Isaac, Zacharia, Isaacs, John D., Iversen, Maura D., Jabs, Douglas A., Jaimungal, Sarada, James, Judith A., Javaid, M. Kassim, Javidan, Pooya, Javier, Rose-Marie, Jefferis, Roy, Johnsen, Alyssa K., Jordan, Joanne M., Joyce, Andrew A., Jung, Michelle, Kado, Ruba, Kaisho, Tsuneyasu, Kallenberg, Cees G.M., Kane, David, Kaplan, Mariana J., Karsdal, Morten Asser, Kassimos, Dimitrios G., Kastner, Daniel L., Kawano, Mitsuhiro, Kay, Jonathan, Keating, Richard M., Kelly, Jennifer A., Kendler, David, Khamashta, Munther A., Khan, Irfan R., Khanna, Dinesh, Klokkerud, Mari, Kolstad, Kathleen D., Kottyan, Leah, Kraus, Virginia Byers, Kvien, Tore K., Lafyatis, Robert, Landewé, Robert B.M., Langford, Carol A., Lau, Arthur N., Lavin, Robert A., Laxer, Ronald M., Learch, Thomas J., Leatherwood, Cianna, Lewis, Jennifer S., Lewith, George, Liao, Katherine P., Lightfoot, Adam P., Littlejohn, Geoffrey O., Lorenzo, Pilar, Lories, Rik J.U., Luger, Thomas A., Lundberg, Ingrid E., Luqmani, Raashid A., Lythgoe, Hanna M., MacDougall, Kristin J., MacKenzie, C. Ronald, Manasson, Julia, Mangham, David Charles, Mao, Rong, March, Lyn M., Marqués, Alejandro Olivé, Márquez, Javier, Martín-Mola, Emilio, Martínez-Lavín, Manuel, Matteson, Eric L., Matzat, Stephen J., Mayes, Maureen D., McAlindon, Timothy, McCabe, Candy S., McCarthy, Edward F., McCarthy, Geraldine M., McDermott, Michael F., McGonagle, Dennis, McLean, Lachy, Ian Melville, Andrew Robert, Michou, Laëtitia, Middleton, Rob, Mikdashi, Jamal A., Miller, Frederick W., Miller, Paul D., Minden, Kirsten, Miner, Jonathan J., Moe, Rikke Helene, Möller, Ingrid, Monach, Paul A., Mons, Barend, Myasoedova, Elena, Nam, Jackie L., Namur, Gauthier, Naredo, Esperanza, Neerinckx, Barbara, Nelson, Amanda E., Nicolson, Philippa J.A., Nieves, César E. Fors, Nordal, Ellen B., Nöth, Ulrich, Ntatsaki, Eleana, Oddis, Chester V., Omar, Ahmed, Ombrello, Michael J., Omisade, Antonina, Ong, Voon H., Önnerfjord, Patrik, Orcel, Philippe, Orr, Carl, O'Shea, John J., Ospelt, Caroline, Özen, Seza, Parker, Matthew J.S., Patrono, Carlo, Pilkington, Clarissa A., Pillinger, Michael H., Pineda, Carlos, Pipitone, Nicolò, Poddubnyy, Denis, Pope, Janet E., Postolova, Anna, Price, Andrew, Quartuccio, Luca, Rackwitz, Lars, Radner, Helga, Raychaudhuri, Soumya, Redmond, Anthony C., Rees, Jonathan L., Reeves, Westley H., Rehaume, Linda M., Remmers, Elaine F., Requena, Luis, Reynolds, Gary, Ribbens, Clio, Richards, Bethan, Richardson, Bruce C., Richette, Pascal, Richter, Adrian, Ritchlin, Christopher T., Ritter, Susan Y., Robinson, William H., Rogers, Valerie, Rosas, Ivan O., Rosenthal, Ann K., Rowan, Andrew D., Rudwaleit, Martin, Rull, Marina, Rygg, Marite, Saag, Kenneth G., Salmon, Jane E., Salter, Donald M., Salvarani, Carlo, Sandell, Linda J., Sandigursky, Sabina, Saxne, Tore, Schaible, Hans-Georg, Scher, Jose U., Schett, Georg, Schiffenbauer, Adam I., Schiller, Alan L., Schlesinger, Naomi, Schreiber, Benjamin E., Schwartz, Daniella Muallem, Shapiro, Lauren M., Sharma, Leena, Siaton, Bernadette C., Siegel, Richard M., Sieper, Joachim, Simard, Julia Fridman, Simmons, Barry P., Simms, Robert W., Singer, Nora G., Smith, Judith A., Smith, Stacy E., Smolen, Josef S., Solomon, Daniel H., Stack, John, Stanley, David, Steen, Virginia D., Steere, Allen C., Steiner, Günter, Steinert, Andre F., Stojan, George, Strand, Vibeke, Straub, Rainer H., Streeten, Elizabeth A., Superti-Furga, Giulio, Tak, Paul P., Tang, Chen, Taylor, Peter C., Terkeltaub, Robert, Thomas, Beje, Thomas, Ranjeny, Thorne, Jennifer E., Tobias, Jonathan H., Tremoulet, Adriana H., Trouw, Leendert A., Tuan, Rocky S., Turesson, Carl, Umehara, Hisanori, Valdes, Ana M., van der Heijde, Désirée, van Vollenhoven, Ronald F., Vanderstukken, Joke, Varga, John, Vassilopoulos, Dimitrios, Veale, Douglas J., Viatte, Sebastien, Vincent, Tonia, Vital, Edward M., von Loga, Isabell S., Wallace, Daniel J., Walsh, Nicola, Warber, Sara L., Warburton, Gary, Ward, Robert J., Watts, Laura, Watts, Richard A., Wedderburn, Lucy R., Weinblatt, Michael E., Weir, Matthew R., Sr., Weisman, Michael H., Weiss, Pamela F., Wenham, Claire Y.J., West, Sterling G., White, Harriet Branford, White, Kenneth E., Wilkinson, David J., Williams, David E., Williams, Richard, Wilson, Hannah, Winthrop, Kevin L., Witt, Claudia M., Witzmann, Gerhard, Wong, John B., Woolf, Anthony D., Wordsworth, Paul B., Worthington, Jane, Wysham, Katherine D., Xu, Huji, Young, David A., Young, Stephen P., Yusof, Md Yuzaiful Md, Zhuang, Haoyang, and Zink, Angela

Published
2019
Full Text
View/download PDF

46. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Author

Smolen, Josef S., Landewe, Robert, Breedveld, Ferdinand C., Buch, Maya, Burmester, Gerd, Dougados, Maxime, Emery, Paul, Gaujoux-Viala, Cecile, Gossec, Laure, Nam, Jackie, Ramiro, Sofia, Winthrop, Kevin, de Wit, Maarten, Aletaha, Daniel, Betteridge, Neil, Bijlsma, Johannes W. J., Boers, Maarten, Buttgereit, Frank, Combe, Bernard, Cutolo, Maurizio, Damjanov, Nemanja, Hazes, Johanna M. W., Kouloumas, Marios, Kvien, Tore K., Mariette, Xavier, Pavelka, Karel, van Riel, Piet L. C. M., Rubbert-Roth, Andrea, Scholte-Voshaar, Marieke, Scott, David L., Sokka-Isler, Tuulikki, Wong, John B., van der Heijde, Desiree, Smolen, Josef S., Landewe, Robert, Breedveld, Ferdinand C., Buch, Maya, Burmester, Gerd, Dougados, Maxime, Emery, Paul, Gaujoux-Viala, Cecile, Gossec, Laure, Nam, Jackie, Ramiro, Sofia, Winthrop, Kevin, de Wit, Maarten, Aletaha, Daniel, Betteridge, Neil, Bijlsma, Johannes W. J., Boers, Maarten, Buttgereit, Frank, Combe, Bernard, Cutolo, Maurizio, Damjanov, Nemanja, Hazes, Johanna M. W., Kouloumas, Marios, Kvien, Tore K., Mariette, Xavier, Pavelka, Karel, van Riel, Piet L. C. M., Rubbert-Roth, Andrea, Scholte-Voshaar, Marieke, Scott, David L., Sokka-Isler, Tuulikki, Wong, John B., and van der Heijde, Desiree

Abstract

In this article, the 2010 European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and bDMARDs, respectively) have been updated. The 2013 update has been developed by an international task force, which based its decisions mostly on evidence from three systematic literature reviews (one each on sDMARDs, including glucocorticoids, bDMARDs and safety aspects of DMARD therapy); treatment strategies were also covered by the searches. The evidence presented was discussed and summarised by the experts in the course of a consensus finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) were determined. Fourteen recommendations were developed (instead of 15 in 2010). Some of the 2010 recommendations were deleted, and others were amended or split. The recommendations cover general aspects, such as attainment of remission or low disease activity using a treat-to-target approach, and the need for shared decision-making between rheumatologists and patients. The more specific items relate to starting DMARD therapy using a conventional sDMARD (csDMARD) strategy in combination with glucocorticoids, followed by the addition of a bDMARD or another csDMARD strategy (after stratification by presence or absence of adverse risk factors) if the treatment target is not reached within 6months (or improvement not seen at 3months). Tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, biosimilars), abatacept, tocilizumab and, under certain circumstances, rituximab are essentially considered to have similar efficacy and safety. If the first bDMARD strategy fails, any other bDMARD may be used. The recommendations also address tofacitinib as a targeted sDMARD (tsDMARD), which is recommended, where licensed, after use of at least one bDM

Published
2014

50. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Author

Smolen, Josef S, primary, Landewé, Robert, additional, Breedveld, Ferdinand C, additional, Buch, Maya, additional, Burmester, Gerd, additional, Dougados, Maxime, additional, Emery, Paul, additional, Gaujoux-Viala, Cécile, additional, Gossec, Laure, additional, Nam, Jackie, additional, Ramiro, Sofia, additional, Winthrop, Kevin, additional, de Wit, Maarten, additional, Aletaha, Daniel, additional, Betteridge, Neil, additional, Bijlsma, Johannes W J, additional, Boers, Maarten, additional, Buttgereit, Frank, additional, Combe, Bernard, additional, Cutolo, Maurizio, additional, Damjanov, Nemanja, additional, Hazes, Johanna M W, additional, Kouloumas, Marios, additional, Kvien, Tore K, additional, Mariette, Xavier, additional, Pavelka, Karel, additional, van Riel, Piet L C M, additional, Rubbert-Roth, Andrea, additional, Scholte-Voshaar, Marieke, additional, Scott, David L, additional, Sokka-Isler, Tuulikki, additional, Wong, John B, additional, and van der Heijde, Désirée, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results